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Twenty-five prostatic adenocarcinomas were 
studied for the presence of intratumoral cytoge- 
netic heterogeneity by interphase in situ hybridiza- 
tion (ISH) to routinely processed tissue sections. 
ISH with a chromosome Y-specific repetitive DNA 
probe provided a model to investigate patterns of 
chromosomal heterogeneity within and between 
different pathological grades. The Gleason grading 
system was used, since it is based on a detailed clas- 
sification of growth patterns. Heterogeneity with re- 
spect to ploidy of the tumor was examined by ISH 
with a repetitive DNA probe specific for chromo- 
some 1. The ploidy status of these cancers was con- 
firmed by DNA flow cytometry (P < 0.001). Cytoge- 
netic heterogeneity at the (Y) chromosomal level 
was observed between Gleason areas, within one 
area, and even within single tumor glands. The dif- 
ferent patterns of chromosomal heterogeneity were 
seen in all tumor grades and stages. Differences in 
ploidy status were also found following the afore- 
mentioned histological patterns, again, in all grades 
and stages. Intraglandular heterogeneity was most 
frequently seen. No correlation was found between 
cytogenetic heterogeneity and proliferative activity 
(Ki-67 immunostaining). In contrast to current 
views on clonality, suggesting regional separation 
of subclones with different DNA content, this study 
demonstrates that these subclones can be inter- 
spersed. o 1995 wiley-Liss, hc. 
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Prostate cancer, which is now exceeding lung cancer 
as the most commonly diagnosed cancer in American 
men (9 ) ,  is known for its highly heterogeneous histolog 
ical appearance ( 13). Foci within a prostate show varying 
degrees of differentiation and may contain cells that dif- 
fer genetically. Additionally, the complex tissue architec- 
ture [often comprising normal epithelium, stromal cells, 
benign prostatic hyperplasia (BPH), and prostatic in- 
traepithelial neoplasia (PIN) within the tumor mass] has 
complicated analysis of prostatic tumors by conventional 
cytogenetic analysis. Karyotyping studies of prostate can- 
cers are further hampered by the low-mitotic index of 
prostatic tumor cells and subsequent overgrowth in tis- 
sue culture of (normal) stromal or epithelial cells. JSary- 
otyping of prostatic tumors has shown recurrent chro- 
mosomal aberrations of chromosome arms 7q and 1 O q ,  
loss of Y, and trisomy of chromosome 7 (2,5,27,29), and 
restriction fragment length polymorphism (RFLP) studies 
have revealed loss of alleles on 8p, lop, loq, 16q, and 18q 
arms (3,6,25). However, a clinically important chromo- 
somal abnormality in prostatic cancer has yet to be iden- 
tified. 
In general, cytogenetic heterogeneity is a common fea- 
ture of solid (epithelial) tumors (17,21,28,32,43). Only 
limited data are available concerning cytogenetic heter- 
ogeneity in prostatic tumors (4,26,29). Lundgren et al. 
( 2 6 )  have demonstrated by karyotyping studies that pa- 
tients with clonal chromosomal abnormalities had a poor 
outcome, compared with those who had non-clonal ab- 
errations. Intratumoral heterogeneity in ploidy status of 
prostatic tumors has also been revealed by DNA flow 
cytometry (FCM) (4 ,243  1 ). Both aneuploidy/tetraploidy 
and diploidy have been detected when several biopsies 
per tumor were analyzed (4,24,31). Likewise, FCM DNA 
studies of multiple samples from different sites in one 
tumor and/or metastases have shown heterogeneity in 
DNA in lung cancers (7,38),  gliomas (lo), pancreatic 
tumors (39), gastrointestinal cancers ( 11,38), and ovar- 
ian carcinomas ( 15). In addition, in epithelial tumors 
such as bladder cancer (19,20,35), breast cancer ( 1 2 ) ,  
and lung cancer (22 ) ,  cytogenetic heterogeneity has 
been revealed by interphase cytogenetics. 
Interphase cytogenetic analysis by in situ hybridization 
(ISH) has been increasingly utilized to detect specific 
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chromosomal abnormalities and their relation to progres- 
sion in neoplasms. Most investigators have used cell sus- 
pensions from disaggregated tumor blocks (e.g., 19,41). 
However, the inevitable loss of tissue architecture pre- 
vents the detection of relationships between chromo- 
some changes and histopathological characteristics. To 
circumvent these problems, we have applied ISH to ar- 
chival paraffin-embedded tissue sections (23,40,42). 
In the present study we addressed the following ques- 
tions: 1) Does chromosomal heterogeneity exist within 
prostatic tumors, and if so, at what histological levels 
(glands, areas)? 2) Is the ploidy status of the tumors het- 
erogeneous? and 3) Are there any correlations between 
cytogenetic characteristics and proliferative activity of 
the tumor cells? 
MATERLALS AND METHODS 
Tissue Preparation 
Routinely processed, formalin-fixed, paraffin-embed- 
ded tissues, obtained between 1990 and 1992 from rad- 
ical prostatectomies of 25 patients with primary prostatic 
adenocarcinoma, were used for this study. Tumors were 
staged according to the TNM classification (36) and 
graded according to the Gleason system ( 13). The Glea- 
son grading system recognizes five growth patterns with 
increasing loss of histological differentiation from grade 
1 to 5. A tumor is assigned a certain Gleason score by 
adding the grades of the two dominant growth patterns 
(13). Forty-one Gleason areas were discriminated in our 
panel of 25 prostatic tumors. 
In situ hybridization (ISH) was performed on consec- 
utive 4 pm tissue sections. Sections were mounted with 
distilled water on aminoalkylsilane (Sigma, St. Louis, MO) 
coated microscope glass slides and baked overnight at 
60°C for better adherence. 
Probe Selection 
Probes specific for chromosome 1 and Y were selected. 
Selection criteria were based on literature data consider- 
ing numerical (and structural) aberrations in prostate and 
other solid tumors. As described above, loss of the Y 
chromosome is reported in prostatic cancer (2,5,27, 
29,40). Furthermore, the Y probe was best suited for 
visualizing heterogeneity in the prostatic tumors, since 
loss of the Y chromosome is easily recognized. A probe 
specific for the centromeric region of chromosome 1 was 
chosen to quantify the rate of aneuploidy of the tumors. 
N o  recurrent numerical aberrations were found for this 
chromosome in karyotyping studies (2,5,27,29), as well 
as in an ongoing investigation by our own group (1). 
In Situ Hybridization 
ISH was performed as previously described (23,42). 
The (peri)centromeric repetitive satellite DNA probes 
were labeled with biotin- 14-DATP by nick translation of 
complete plasmid DNA according to the manufacturer’s 
directions (BRL, Gaithersburg, MD). Briefly, tissue sec- 
tions were deparaffinized and then treated with 0.3% 
H 2 0 2  in methanol for 20 min to block endogenous per- 
oxidase activity. To facilitate DNA probe accessibility to 
the cellular DNA, sections were digested with 0.4% pep- 
sin (Sigma) in 0.2 M HC1 at 37°C for 5-30 min (mean, 14 
min), after an incubation in 2 X  standard saline citrate 
(SSC; pH 7.0) at 70°C for 30 min to shorten the digestion 
time. 
Both cellular DNA and the chromosome-specific repet- 
itive DNA probes were heat denatured. The hybridization 
mixture contained 1-2 b&/ml probe DNA, 500 pgml son- 
icated herring sperm DNA (Sigma), 0.1% Tween-20, 10% 
dextran sulphate, and 60% formamide in 2 X SSC at pH 
7.0. The slides were then incubated overnight at 37°C 
and subsequently washed. 
Histochemical detection was performed by immu- 
noperoxidase diaminobenzidine (DAB) staining as 
previously described. Finally, the sections were counter- 
stained with hematoxylin, rinsed in tap water, dehy- 
drated, and mounted in Malinol (Chroma-Geselschaft, 
Kongen, Germany). 
Evaluation of ISH results 
The centromere 1 and Y DNA probes, as well as the 
autosomal control DNA probes, were analyzed for each 
prostate adenocarcinoma on consecutive 4 pm sections 
in a tumor area to which a certain Gleason score had 
been assigned. A section size of 4 pm was chosen after 
evaluating the degree of nuclear overlap (is., countabil- 
ity) and section thickness. On each tissue section leuko- 
cytes, BPH, nerve cells, etc., served as internal controls to 
evaluate the quality of 1SH and to detect probe polymor- 
phisms. For each of the probes, 100 “intact” (i.e., spher- 
ical) and non-overlapping 4 pm nuclear slices were 
counted by two independent investigators and the num- 
ber of solid DAB spots per nuclear contour was scored 
(0, 1,2, 3,4,  >4 spotshuclear slice). The individual DNA 
probe spot distributions were then compared and to- 
talled, when no significant counting differences between 
the investigators were found. In our series no discrepan- 
cies emerged using this approach. Tumor aneuploidy was 
determined by calculating the percentage of hyperdiploid 
cells in the dominant Gleason area( s). Heterogeneity for 
chromosomes 1 and Y was scored by both careful inspec- 
tion and counting of the aberrant areas. 
Validation of ISH results 
Two types of artefacts could interfere with the analysis 
of heterogeneity, defined by ISH to routine tissue sec- 
tions: 1) the effect of truncation of the nuclei, which 
causes disturbances, (most importantly) at the tumor 
glandular level; and 2) the efficiency of hybridization, 
leading to regional differences. Loss of the Y chromo- 
some within one tumor gland was not caused by artefacts 
due to truncation of nuclei. Previous studies by our 
group (23,42) revealed that an average of 65% of the 
cells displays an ISH Y-spot in truncated (normal) nuclei 
of various histologies. This distribution is in sharp con- 
trast to tumor glands with loss of Y. Furthermore, to rule 
out a possible contamination of Y-less tumor cells within 
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FIG. 1. Bar histograms showing ISH spot distributions for the chromosome Y-specific DNA probe on 4 pm 
tissue sections. A ISH patterns of Gleason areas with (partial) loss ofY in cases 1 ,  3,  18, 19, and 25. B: Control 
cells from the same sections of the aforementioned cases (e.g., leukocytes, normal prostatic glands). In control 
cells the percentage of cells with 1 spot for Y is between 60 and 70%. Note that Y-loss is seen as a shift to the 
left in the distributions. 
one gland with normal preexistent cells that still carry 
the Y chromosome, cytopathology was checked in adja- 
cent hematoxylin and eosin-stained slides. In case of in- 
traglandular heterogeneity for ploidy, truncation of the 
nuclei cannot result in spot distributions as observed in 
this study. If a tumor gland were to be fully tetraploid or 
aneuploid, a distribution of ISH spots would be created 
with more than 50% of the cell nuclei carrying three or 
four hybridization spots for chromosome 1, as described 
previously by us (42). By contrast, we most frequently 
observed a few tetraploid cells in a diploid background. 
Insufficient ISH, leading to regional artefacts, can be 
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FIG. 2. Schematic drawing of histological patterns of cytogenetic het- 
erogeneity in prostatic adenocarcinoma as detected by interphase q t o -  
genetics. Nuclei that are different with respect to chromosomal and/or 
ploidy status are depicted in different shades. Three distinct histological 
patterns were discriminated. A: Intraglandular heterogeneity: neighbor- 
ruled out for the following reasons: 1)  stromal cells ad- 
jacent to tumor glands always showed strong ISH signals, 
thus eliminating focal misinterpretations; and 2) ISH was 
controlled in adjacent sections hybridized with autoso- 
mal DNA probes; this prevented false interpretations at a 
more regional level. We never observed areas within one 
section with loss of ISH signal in both tumor and neigh- 
boring stromal cells. These artefacts could be seen when 
the tissue had different accessibility for the probe in dif- 
ferent areas (e.g., due to variable fixation). 
Immunohistochemistry 
Primary labelling of the Ki-67 antigen was performed 
with a monoclonal antibody, MIB- 1 (Immunotech, 
Marseille, France), diluted 1/100 in phosphate-buffered 
saline (PBS) (8). Immunohistochemistry was performed 
using the routine ABC-immunoperoxidase method (Vec- 
tor). For each specimen 200 tumor cells in the marked 
Gleason areas were counted randomly by two indepen- 
dent investigators. 
DNA Flow Cytometry 
DNA content of the paraffin material was measured as 
described by Hedley et al. (16) .  Gleason-graded tumor 
areas were selectively cut out of the paraffin blocks. In 
eight cases (32%) the two dominant Gleason growth 
patterns were present within the same tissue block and 
could not be separated. Correspondence (presence of tu- 
mor, tumor grade) between upper and lower boundary 
was seen in 93% of the tumor samples. In only 3 of 41 
areas (7% ) was the tumor area not present at the lower 
boundary. Flow cytometry and analysis of the ethidium 
bromide (Sigma) stained nuclei from these areas was per- 
formed using a Facscan (Becton Dickinson, Mountain 
View, CA). Tissue from a normal prostate served as a 
diploid control. A DNA index between 0.9 and 1.1 was 
considered diploid. The percentage of non-2C peak cells 
INTERREGIONAL 
ing cells are cytogenetically different. B: Intraregional heterogeneity: 
within one Gleason area, neighboring tumor glands show cytogenetical 
differences. C: Interregional heterogeneity. One Gleason area is cytoge- 
netically different from another. 
was derived from the flow histograms and used to deter- 
mine the percentage of aneuploidtetraploid cells of the 
dominant Gleason area(s) within one tumor. 
RESULTS 
Chromosomal Heterogeneity 
Loss of chromosome Y was used as a model system to 
study chromosomal heterogeneity. In our panel of 25 
radical prostatectomies we found loss of the Y chromo- 
some in five cases (seven Gleason-graded areas; Fig. 1A). 
Loss of the Y chromosome was never observed in control 
cells, present on the same tissue section (Fig. 1B). Loss of 
Y was seen in both low and high grade tumors (Table I ). 
Heterogeneous loss of this chromosome was seen at 
three levels of aggregation: intraglandular, intraregional, 
FIG. 3. (Figure on page 88.) A ISH with the chromosome Y-specific 
DNA probe to the Gleason 2 area of case 3, showing intraglandular 
chromosomal heterogeneity: loss of chromosome Y can be seen in most 
tumor cell nuclei (large arrows), whereas some cancer cells still contain 
the Y chromosome (small arrows). At least ten neighboring cancer cell 
nuclei with Y-loss are seen to line up in this gland. The ISH-related spots 
were visualized with immunoperoxidase/DAB (black), and hematoxylin 
was used as a counterstain (gray). B: ISH with the Y-specific probe to the 
Gleason 2 area of case 1, showing intraregional heterogeneity. Foci of 
tumor glands without Y chromosome (large arrows) and with chromo- 
some Y (small arrows), both situated in one Gleason area, are shown. C: 
Detail of B, showing Y-loss in tumor glands. D: Detail of B, showing 
retention ofY in other tumor glands. E: ISH with the chromosome l-spe- 
cific (control) probe to the same area of case 1. N o  differences in ISH- 
related spot pattern for this probe can be seen between foci without 
(large arrows) and with (small arrows) the Y chromosome, thus elimi- 
nating the possibility of different hybridization efficiency between the 
two areas. F: ISH with the Y probe to the Gleason 5 area of case 18. Y-loss 
is seen in the cancer cells (large arrows), but not in the stromal cells 
(small arrows). G: Same case, showing the Gleason 3 area: in these tumor 
glands the Y chromosome is present. This case illustrates interregional 
chromosomal heterogeneity. A 4 0  X objective was used in A, C, D, F, and 
G and a 20 X objective in B and E. 
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Table 1 
Results of Pathological GradinglStaging, Flow Cytometry (FCM), and In Situ 
Hybridization (ISH) 
Case Grade Type" Stageb FCMC ISH aneuploidy* (% ) Y-ISH 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
~ 
4 
5 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
10 
10 
10 
G2 
G2 
G3 
G2 
G3 
G2 
G3 
G2 
G3 
G2 
G3 
G3c 
G3c 
G3c 
G3 
G3 
G4 
G3 
G4 
G3c 
G4 
G3 
G4 
G3 
G4 
G3c 
G4 
G3 
G5 
G3 
G5 
G3c 
G5 
G4 
G4 
G5 
G4 
G5 
G5 
G5 
T3NO 
T4N2 
T2NO 
T3NO 
T2NO 
T2NO 
T2NO 
T3NO 
T3NO 
T3NO 
T3NO 
T3NO 
T3NO 
T3NO 
T3NO 
T4NO 
T3NO 
T4NO 
T3NO 
T3N1 
T3NO 
T4NO 
T2NO 
T3NO 
4 -Y 
6 
2.5 
23 -Y 
21.5 -Y 
8 
6.5 
37.5 
3 
0.5 
1 
8 
1.5 
4.5 
1 
2 
5.5 
2 
9.5 
12 
30.5 
1 
2 
2 
24.5 
46 
4.5 
32 
21.5 
1.5 
2 
19 
18 
23 
4 
2.5 
30 
41 
42 
-Y 
-Y 
-Y 
"Dominant Gleason growth pattern(s). 
bnVM classification: All tumors MO. 
cD(iploid):0.9<Di< 1.1 and4CpeakS lO%;T(etraploid):0.9<Di< 1.1 and4Cpeak> 10%; 
A(neup1oid) Di < 0.9 or Di > 1.1. Values between parentheses are percentage non-2C peak FCM. 
dPercentage of cells with > 2 spotshuclei for chromosome 1. All control cells revealed < 2.5% 
hyperdiploid cells. 
'Shoulder in the DNA histogram. 
and interregional (Fig. 2). In detail, loss of the Y chro- 
mosome was seen in some cells within one tumor gland, 
whereas other cells in the same gland still contained the 
Y chromosome, thus displaying intraglandular heteroge- 
neity (Figs. ZA, 3A). Foci of glands that lost chromosome 
Y and foci of glands that showed the normal spot distri- 
bution for Y alternated within one Gleason area (intra- 
regional heterogeneity; Figs. 2B, 3B-E). The third dis- 
tinct pattern of heterogeneity, termed interregional 
heterogeneity, defined loss of the Y chromosome in one 
Gleason area, whereas the other Gleason area retained 
the chromosome (Figs. 2C, 3F,G; Table 1). Furthermore, 
the three different patterns of chromosomal heterogene- 
FIG. 4. A: ISH with the chromosome 1-specific probe to the Gleason 2 
area of case 3. lntraglandular differences in ploidy can be seen between 
neighboring cells. A few aneuploid cell nuclei with three or four spots 
are arrowed. B: Same case: intraglandular heterogeneity showing slightly 
more aneuploid nuclei (arrows). Note that, in general, these nuclei are 
larger in size than those with one or two spots. C: Same case: ISH with the 
chromosome 7-specific (control) probe to the same area. This probe 
displays the same ploidy pattern. A few aneuploid nuclei are arrowed. D: 
ISH with the centromere 1-specific probe to the Gleason 2 area of case 
5. Many aneuploid nuclei can be distinguished, and a few are arrowed. E: 
Neighboring cancer glands within the same area contain cells mostly 
showing two spots per nucleus (intraregional heterogeneity). F: Gleason 
3 area: ISH with the centromere 1 probe to the cribriform gland (case 
16). Many aneuploid nuclei are visible. G: Same case, Gleason 4 area: 
most nuclei display two spots. Case 16 illustrates interregional hetero- 
geneity in ploidy. A 40 x objective was used in A-G. 
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CASE 3 (G2) CASE 5 (G2:Area 1) 
80 
60 
Percentage Percentage 
I A  100 
100 
D 
- 
- 
60 "1 
Y1 
Y7 
#I0 
8ol 60 
0 1 2 3 4 ,4 
12 41 46 2 0 0 
10.6 38.6 46 6.6 0.6 0 
12 38 46 4 0 0 
Number of spota/NucIeu8 
60 
60 
CASE 5 (G2:Area 2) 
Percentage 
I c  100 
E 
- 
- 
60 8ol 
Y1 
Y7 
# I 0  
40 
20 
n 
0 1 2 3 4 ,4 
6.6 37 62 4.6 0 0 
9.6 42.6 46.6 1 0.6 0 
7.6 41 47.6 3.6 0.6 0 
Number of spotaINucleus 
my1 m y 7  o w 1 0  
CASE 16 (G4) 
40 
20 
n 
I = # I  m x 7  c 3 W l O  I 
1 
19.6 
20.6 
20 
2 
40 
41 
46 
3 4 P4 
26 116 0 
26 7 1 
20 10.6 0 
Number of spots/Nucleus 
1 my1 m w 7  U Y l O  I 
20 
n 
16.6 31 
16.6 37.6 30.6 13 
Number of spcts/Nucleus 
my1 my7 U W l O  
FIG. 5. ISH spot distributions for chromosomes 1, 7, and 10 of consecutive tissue sections of all cases shown 
in Figure 4. A: Gleason 2 area of case 3. B: Aneuploid part of Gleason 2 area of case 5. C: Less aneuploid part 
of Gleason 2 area of case 5. D: Gleason 3 area of case 16. E: Gleason 4 area of the same case. The spot 
distributions for these chromosomes are highly comparable. It illustrates equal hybridization conditions for all 
these probes. 
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ity, illustrated by Y-loss, occurred in both low-grade (n 
= 2; Gleason score 5 6)  and high-grade (n = 3; Gleason 
score 2 7) tumors. 
Heterogeneity in Ploidy 
A probe specific for the centromere region of chromo- 
some 1 was used to assess the ploidy status of the tumor 
cells within the dominant Gleason growth pattern( s) 
(Table 1). Aneuploidy defined by ISH correlated well 
with aneuploidyketraploidy measured by DNA FCM (P < 
0,001, Pearson’s rank correlation). Heterogeneity in 
ploidy, demonstrated by ISH with the DNA probe specific 
for chromosome 1, revealed the same three patterns that 
were distinguished for chromosomal heterogeneity (Fig. 
2). Intraglandular heterogeneity resulted in differences in 
spot number for chromosome 1 between neighboring nu- 
clei (Figs. 2A, 4A,B). Control probes for other chromo- 
somes, e.g., chromosome 7, showed comparable hybrid- 
ization patterns in the same tumor glands (Figs. 4C, 5A). 
Intraregional differences within one Gleason area were 
seen in, for example, the Gleason 2 area of case 5. One 
part of this area was highly aneuploid, whereas another 
part showed a more diploid distribution (Figs. 4D,E, 
5B,C). Interregional heterogeneity for ploidy between 
different Gleason areas was distinguished in several cases 
(Table 1). This is illustrated by an aneuploid cribriform 
growth pattern (grade 3 )  and another poorly differenti- 
ated area (grade 4) of case 16, which displayed a rather 
diploid distribution (Figs. 4F,G, 5D,E). In all these cases 
control probes showed the same spot distribution as 
chromosome 1 (Fig. 5). No significant differences in the 
occurrence of the three aforementioned histological pat- 
terns were observed between low- and high-grade tu- 
mors (Fig. 6) .  lntraglandular heterogeneity was most fre- 
quently detected. 
Proliferative Activity 
Immunohistochemistry (IHC) with a Ki-67 antibody 
(MIB-1) in normal and hyperplastic glands demonstrated 
less than 2.5% positive immunostaining of the nuclei. In 
tumor cells the percentages of stained nuclei varied from 
1 % to 28% (mean, 8% ). No differences of MIB- 1 staining 
patterns were observed between parts of a tumor with or 
without chromosome (Y) loss (not shown). Likewise, 
heterogeneity in ploidy of the tumor cell nuclei did not 
result in differences in proliferation rate as assessed by 
MIB-1 IHC. 
DISCUSSION 
In this study we were able to distinguish cytogenetic 
heterogeneity in prostatic adenocarcinomas by means of 
ISH to routine paraffin sections. This approach retained 
the tissue architecture, allowing detection of cell subsets 
with different karyotypes. Control studies were per- 
formed for, e.g., the effect of truncation of the nuclei and 
variation in hybridization efficiency. Three patterns of 
cytogenetic heterogeneity could be distinguished: in- 
traglandular, intraregional, and interregional (Gleason ar- 
eas). Heterogeneity for both chromosomal status and 
FIG. 6. Bar histogram of the distribution of the three different patterns 
of heterogeneity in ploidy with respect to pathologic grade. Heteroge- 
neity of ploidy status can be found in both low- and highgrade tumors. 
chromosome 1 ISH defined ploidy occurred in these 
three patterns. Cytogenetic heterogeneity at the chromo- 
somal level was defined by loss of chromosome Y. Loss of 
Y is the most common chromosomal aberration in pros- 
tatic cancer (2,5,27,29). The importance of (loss of) the 
Y chromosome is not clear. In some cancers loss of Y is a 
possible prognostic parameter (33 ) .  In our panel no cor- 
relation was found between age of the patient and loss of 
the Y chromosome, as has been reported previously (34) .  
Further, control cells, e.g., leukocytes, always retained 
the Y-chromosome. We observed heterogeneity for Y-loss 
even within one tumor gland. In our series of tumors we 
did not observe significant differences in the occurrence 
of the described histological patterns for Y-loss hetero- 
geneity between low- and high-grade tumors. Although 
the number of tumors with Y-loss is too small for statis- 
tical evaluation, our data suggest that with tumor progres- 
sion the Y-loss pattern does not change dramatically. 
Chromosome 1 was used as a measure for ploidy sta- 
tus. In a previous study no abnormalities of this chromo- 
some occurred ( 1 ). Further, tumor aneuploidy, defined 
by ISH for chromosome 1, was confirmed by DNA FCM. 
Similar results were obtained by us in other organ sys- 
tems (23,42). FCM is not suitable for the detection of 
subtle focal differences. This study shows that neighbor- 
ing nuclei within one tumor gland contained different 
copy numbers of chromosome 1 and therefore they differ 
in DNA content. Surprisingly, it appeared to be the most 
frequent ploidy pattern. These data suggest that “single 
cell heterogeneity” exists aside from focal differences. 
The latter is seen by us as intra- and interregional heter- 
ogeneity. In our study we did not observe significant 
variation in the incidence of the three types of heteroge- 
neity between low- and high-grade tumors. Apparently, in 
high-grade tumors ploidy differences can still exist at 
various levels, due to continuous genetic instability, 
rather than expansion into one single pattern (30 ) .  
Clonal karyotypic changes in prostatic tumors were 
also found by others (4,26,29). In most karyotyping stud- 
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ies a clone is defined as two or more cells with the same 
karyotype, or three or more cells with the same numer- 
ical aberration. Micale et al. (29) reported that clonal 
aberrations were confined to tumors in advanced stages. 
Henke et al. ( IS )  used interphase cytogenetics and found 
that focal abnormalities occurred only in higher tumor 
grades. These findings are in contrast to our data: We 
distinguished cytogenetic heterogeneity throughout the 
grading and staging spectrum. DNA FCM of multiple sam- 
ples of prostatic adenocarcinomas showed heterogeneity 
in ploidy in more than half of cases (31 ). This multiple 
site sampling demonstrated that single biopsy specimens, 
when used in karyotyping, DNA FCM, and interphase cy- 
togenetics on nuclear suspensions, are hardly representa- 
tive for a given (prostatic) tumor (4,7,31,37,38). At 
present, the clinical importance of DNA ploidy heteroge- 
neity is not clear and varies among the tumours studied 
(10,14,15). 
We conclude that cytogenetic heterogeneity is a very 
prominent feature of prostatic adenocarcinoma. ISH ap- 
plied to routine sections provides us with a tool to dis- 
criminate this phenomenon even at the glandular level. 
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